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Abstract
INTRODUCTION: The combination of positron emission tomography (PET) and magnetic resonance (MR) has become a subject 
of interest for researchers in the recent several years. Positron emission tomography in combination with magnetic resonance 
(PET/MR) is the most recent imaging technique classified in the so called hybrid systems category.
AIM: This review briefly discusses the development history of PET/MR scanners, the principle of their operation, of tandem 
systems, as well as fully integrated devices. Further, it summarizes recent reports on the application of PET/MR scans and their 
possible future role in oncological and non-oncological diagnostics. 
CONCLUSIONS: Recent reports regarding the application of PET/MR scanners show huge potential of simultaneously received 
images, which exceed the advantages of either of those scans used separately. However, the results so far remain uncertain 
and require further investigations, especially in terms of clinical studies, not only for scientific purposes.
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Background
Morphological and molecular imaging using magnetic reso-
nance (MR) or computer tomography (CT) with positron emission 
tomography (PET) plays a key role in oncological diagnostics (stag-
ing before treatment, evaluation of treatment response, detection of 
recurrence etc.), as well as other areas, e.g. cardiology, neurology, 
psychiatry and others. Despite the large role these scans fulfil in 
imaging diagnostics of various conditions, each of them has certain 
well known limitations.
The combination of anatomical and functional images in order 
to improve the quality of the acquired images has already been 
used for a significant time. The end of the 1980s saw the first hybrid 
devices being applied, which are used up to this day and com-
bine single photon emission computer tomography (SPECT) with 
CT [1, 2]. Another hybrid device which completely revolutionized 
imaging diagnostics, especially in the area of oncology, was the 
1998 introduction of PET/CT scanners [3]. In both cases of hybrid 
systems, the more functional imaging methods, i.e. SPECT and 
PET, have been merged with more anatomical images received in 
CT, thereby creating a single image. With the commencement of 
PET/CT scanner use in clinical diagnostics in 2001, it soon turned 
out, that the combination of both scan types into one system 
is beneficial, as it ensures simultaneous anatomic and functional 
imaging [4, 5]. Ever since PET/CT scans have started being used 
routinely, it became obvious, that those scans have a significant 
influence on the therapeutic process in oncology, even in up to 
50% of cases [6].
The creation of hybrid PET/MR devices utilizes the advan-
tages of MR scans over CT which has been currently applied in 
PET/CT scans. The primary advantages of MR include: 
 — possibility of reducing the patient’s exposure to radiation, 
as during the MR scan ionizing radiation is not used, which 
is especially important in case of children, as well as in situa-
tions which require repeated PET scans; 
 — MR ensures high resolution of anatomical and functional ima-
ges, offering better resolution of soft tissue contrast and high 
diversity of tissue contrast compared with CT; 
 — MR, using functional MR imaging (fMRI) and MR spectroscopy 
(MRS), provides additional information which may increase the 
diagnostic efficiency and possibility of quantitative assessment 
of PET scans and may be helpful in handling the patient and 
understanding the tumor biology.
On the other hand, MR has several disadvantages: 
 — significantly longer scan time compared with CT; 
 — contraindications in patients with various metal implants, pace-
makers and foreign bodies; 
 — significantly higher cost compared with CT [7].
History of PET/MR scanner development
The promising results of pre-clinical PET/MR imaging have 
encouraged one of the primary companies dealing in production of 
diagnostic equipment (Siemens) to create the first clinical PET/MRI 
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prototype (BrainPET), created for the purpose of simultaneous PET 
and MR imaging of the brain, which was installed at the University 
of Tübingen in Germany [8, 9]. The system was evaluated in clinical 
conditions for 3 years (2008–2011). The anatomical potential of MR 
was investigated in relation to the high contrast of soft tissues, utiliz-
ing various possibilities of MR scan imaging, i.e. BOLD — a system 
of blood oxygen level dependent MR signal intensity, functional MR 
(fMRI), diffusion-weighted imaging (DWI), perfusion-weighted imag-
ing (PWI) and diffusion tensor imaging (DTI) [10, 11]. In this system, 
the sequential connection of PET and MR was intended for molecu-
lar and genetic imaging of the brain by docking separate PET and 
MR systems connected by a joint bed which moved through the 
field of view of both imaging devices [12]. This was achieved by 
combining two high class devices, namely high resolution research 
tomography (HRRT) and 7 Tesla powered MR (7T MRI). 
Until concurrently, operating PET/MR whole body imaging 
technologies have become more available and economically vi-
able, other approaches, namely sequential PET/MR scans were 
researched [13]. One of such systems is the Philips Ingenuity TF 
PET/MR, which is a hybrid imaging system with a GEMINI TF PET 
component and an Achieva 3.0T X-series MR component [14]. 
Although such a device structure does not allow simultaneous PET 
and MR imaging, it does allow for automatic superimposition of 
sequentially recorded PET and MR images. Such systems have 
been installed in New York (Mount Sinai Medical Center), at the 
University Hospital in Geneva and in Dresden (Forschungszentrum 
Dresden-Rossendorf). Adhering to the structural rules applied when 
building PET/MR scanners for brain imaging, Siemens developed 
a system for simultaneous PET and MR imaging of the whole body 
in the form of the Biograph mMR scanner. The first such device 
was installed in November 2010 at the University in Munich. Sub-
sequent Siemens PET/MR scanners were installed at the Tübingen 
and Erlangen Universities in Germany and in Boston at the Mas-
sachusetts General Hospital. 
In Poland there are currently (2016) two PET/MR scanners in-
stalled, namely at the Center of Oncology in Bydgoszcz and the 
Laboratory of Medical Imaging at the Białystok Science and 
Technology Park. In both instances these are Biograph mMR scan-
ners manufactured by Siemens. 
Technological achievements of PET/MR 
systems
There are currently two types of commercially available de-
vices which combine PET and MR, namely the tandem system, in 
which the PET and MR devices are in one or two rooms, and a fully 
integrated system, in which the PET and MR devices are built into 
one gantry [15–17]. Tandem PET/MR device systems allow for mini-
mal interference between those systems and for that reason require 
only small changes in composition of PET and MR devices. On the 
other hand, fully integrated PET/MR systems require completely 
new structural design and technological solutions. These systems, 
however, make it possible to achieve truly simultaneous acquisi-
tion, which significantly reduces the total acquisition time and the 
spatial requirements [18].
The primary technological challenge is posed by the fact that 
photomultipliers used in traditional PET scanners which register the 
light signal from scintillation crystals are unable to operate within 
a strong magnetic field. Tandem systems circumvent this problem 
by physically separating the devices and appropriately screening 
the individual components. Integrated PET/MR devices manufac-
tured so far use light signal reading semi-conductor technology, 
so called avalanche photodiodes instead of photomultipliers which 
are unaffected by magnetic fields [17].
Another important technological challenge of tandem and 
fully integrated PET/MR systems is photon attenuation correction, 
which is necessary to maintain the correct image of radionuclide 
distribution independent of the tissue density. MR does not provide 
information regarding the radiological density of tissues. That is why 
development of new attenuation correction methods in PET/MR 
systems is required. The method currently used in PET/MR de-
vices is to receive the sequences devoted to MR in order to classify 
voxels in the body into different tissue types, with the omission of 
the cortical layer of bones [19, 20]. This method works reliably at 
the cost of slight underestimation of tracer uptake value in foci of 
increased uptake located inside or in close proximity to the bones, 
in comparison to PET/CT scans. An alternative approach proposed 
for PET data attenuation correction in PET/MR is the one based on 
an atlas (map) [21]. It should be noted that the proposed correction 
techniques apply only to attenuation generated by the patient, and 
not to that caused by scanner equipment components, such as the 
bed on which the patient lies and the massive MR coils [22, 23]. 
For that reason equipment attenuation maps are generated, which 
are stored in the system and included with human attenuation 
maps. Another method of attenuation correction are the so called 
templates. An attenuation map template is created as the mean 
of images from several available transmission scans [24]. An-
other PET data attenuation correction method is a direct approach 
based on segmentation. This approach works directly in standard 
T1-dependent MR images routinely for every patient. The most dif-
ficult task in using these images is the differentiation between bone 
tissue and air-filled spaces, as the same intensity range appears in 
both those tissue types [25]. 
Application of PET/MR scans in oncology
In oncology, imaging scans play a significant role in staging, 
evaluation of treatment response and early detection of recurrence. 
In PET/CT scans involving 18F-FDG a possibility of accurate assess-
ment of the T stage was documented in many diagnoses, e.g. in 
head and neck tumors, non-small-cell carcinoma of the lungs and 
large intestine cancer [26–29]. The evaluation of local tumor inva-
sion is based primarily on morphological data, that is why the MR 
component in PET/MR scans may turn out to be better than CT in 
PET/CT scans, especially in those tumors, in which high soft tis-
sue contrast in MR images would enable higher image accuracy, 
as for example, in breast, prostate, head and neck, liver cancer, 
muscle and bone system or brain tumors. In the case of head and 
neck tumors, studies so far have shown superior results in assess-
ment of local staging achieved by PET/MR scans as compared 
to PET/CT  [30]. In case of breast cancer, MR mammography 
shows high sensitivity and relatively low specificity; however, FDG 
PET/CT scans are more specific and less sensitive [31, 32]. An 
increase in specificity from 53% to 97% was observed by adding 
up data from the PET and MR image [33]. In case of colorectal 
cancer, reports regarding fusion of PET and MR images have not 
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shown superiority compared with PET/CT [34]. When it comes to 
hepatocellular carcinoma (HCC), so far there has been no data 
published regarding PET/MR imaging in the assessment of tumor 
size; however, it seems that the combination of PET and MR images, 
especially fMR — functional MR — will make it possible to achieve 
images better than with PET/CT scans [7]. In primary bone tu-
mors and soft tissue sarcomas the MR scan is the method of choice 
for staging. Because studies so far have shown high accuracy in 
the staging assessment of these tumors in PET/CT scans [35], the 
addition of PET images to MR images would make it possible to 
gain additional information (18F-FDG distribution), which may be 
useful in accurate specification of the biopsy location in tumors and 
planning of surgical procedures and radiotherapy  [36]. Similar 
reports indicating superior accuracy of PET/MR images compared 
to PET/CT were shown in the case of prostate cancer. This is es-
pecially significant in relation to patients with chronically increased 
PSA values and negative biopsy results, for whom a PET/MR scan 
allows for more accurate specification of the biopsy location [37]. 
There is a large amount of reports regarding 18F-FDG PET/CT in 
the assessment of Hodgkin and non-Hodgkin lymphoma staging, 
indicating high accuracy, which has led to the widespread applica-
tion of this method [38–40]. PET/MR scans may be an alternative 
to PET/CT scans for young patients, especially children, in order 
to reduce exposure to ionizing radiation; however, at the moment 
there is only little data on the subject [41].
The FDG PET/CT is more accurate than just a CT in the assess-
ment of N stage of various types of cancer [42]. The advantage 
of the FDG PET/CT scan over a CT scan is the acquisition of ad-
ditional information on lymph node metabolism. It should be noted 
that the size of lymph nodes alone does not enable determination 
of their malignancy, small nodes (< 1 cm) are not always benign, 
and enlarged ones are not always malignant. For that reason, it 
is expected that PET/MR scans, especially fMR will enable detec-
tion of malignant lesions in lymph nodes similarly to, or even with 
higher accuracy than PET/CT. 
Certain studies have compared full-body PET/CT and MR 
scans in the assessment of distant metastases [43–47]. Results are 
varied for anatomically different regions; the PET/CT scan is more 
appropriate for evaluating metastases to the lungs, while MR for 
lesions in the liver, bones, bone marrow and brain. The combination 
of PET and MR imaging may prove significant in the assessment 
of metastasized lesions in those organs, especially in the case of 
bone marrow invasion. 
In various malignancies, the assessment of response to treat-
ment is based on a systematic evaluation of tumor size using cor-
responding criteria, e.g. RECIST; it has been show, however, that 
such evaluation has certain limitations. The application of a PET/CT 
exam has facilitated the assessment of treatment response in case 
of solid tumors, as well as lymphomas, based not only on the size 
of lesions, but also on the assessment of the metabolism [48, 49]. 
In recent years, clinical studies have shown that diffusion-weighted 
MR imaging (DWI) may be useful in the assessment of treatment 
response as well [50–53]. In this context, PET/MR scans, especially 
involving functional MR, can improve treatment result evaluation, 
as well as detection of early relapse [7]. The first prospective re-
search examining the value of PET/MR in evaluating the response 
to treatment in head and neck tumors has shown excellent re-
sults combining a high negative prediction value of PET scans with 
the high sensitivity of MR scans [54]. In other types of malignant 
disease, the potential of PET/MR scans in the evaluation of treat-
ment response or recurrence requires further study.
Application of PET/MR scans in neurology
PET/MR brain imaging, contrary to whole-body imaging, is sig-
nificantly easier, because the examined organ (the brain) may be 
completely scanned within just one bed movement during the scan. 
This decreases the scan duration, which results in a decreased 
amount of data. PET/MR brain scanning is usually comprised of 
various MR sequences T1 and T2 dependent images with or with-
out contrast, MR angiography, diffusion-weighted imaging (DWI), 
perfusion-weighted imaging (DPI), MR spectroscopy (MRS) and 
diffusion tensor imaging (DTI). 
The MR scan is essential in the assessment of most neuro-
logical conditions, while the PET scan provides supplementary 
information in many clinical situations. Due to the high value of 
molecular imaging in dementia diagnostics, the PET tracers have 
been included in guidelines for the assessment of neurodegenera-
tive disorders. PET scans also provide supplementary information 
in patients with brain tumors, epilepsy and stroke. The combina-
tion of the two imaging techniques into one system has become 
a logical solution providing additional information in pathology of 
the central nervous system. 
The imaging of b-amyloid deposits in the brain using PET/MR 
scans of adult patients with cognitive disorders may allow differen-
tiating between such conditions as Alzheimer’s disease (AD), Lewy 
body dementia, dementia in the course of Parkinson’s disease. 
A negative result indicates the presence of a small number of 
amyloid plaques and reduces the probability of the occurrence of 
AD as a cause of a cognitive disorder [55, 56].
In brain tumor imaging, due to the high amino-acid metabolism 
in astrocytes two specific radiopharmaceuticals, namely 18F-FET 
(fluoro-ethyl-tyrosine), 11C-MET (methionine) are useful in the 
differentiation of malignant and benign disease [57]. Boss et.al. 
have used spectroscopic MR and PET using 11C-MET to classify 
ambiguous images in MR in low or high grade gliomas and to de-
tect the most suitable areas for surgical biopsy [58]. Preuss et.al. 
have used the MR scan and 11C-MET for biopsy planning and for 
neuronavigation in children with brain tumors [59].
MR allows for evaluation of the cause of acute brain strokes, 
i.e. ruptured blood vessels or vascular obstruction, as well as the 
size, localization and even reversibility of ischemic lesions. Addition-
ally, MR scans are used to select patients with ischemic strokes, 
who will benefit from thrombolytic treatment within 4.5 h from the 
ischemic event [60]. The term of critical, but reversible decrease 
of cerebral blood flow (CBF) has been transferred from H2O PET 
imaging [15O], where it was originally developed for MR imaging 
[61]. Another technique used to evaluate brain perfusion using 
MR is the method of arterial spin labeling (ASL). Zhang et.al. have 
evaluated brain perfusion of ten healthy subjects simultaneously 
using the ASL technique and H2O PET [
15O]. They have shown 
moderate overestimation of CBF in the arterial spin labeling (ASL 
method) compared to PET, but have also noted a good correla-
tion between the measurements [62]. Despite the fact, that there 
are currently no studies on the subject of PET/MR devices in brain 
stroke diagnostics, it seems that a PET/MR hybrid would be an ideal 
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tool for examining stroke patients, combining, for example, two 
important stroke assessment parameters: diffusion-weighted MR 
imaging (DWI) and quantitative CBF assessment in a PET scan.
In order to identify the focal point of epilepsy prior to surgical 
treatment, MR imaging is the first choice. However, in approximately 
20% of patients with temporal lobe epilepsy (TLE), MR is non-dia-
gnostic or MR and EEG scans are incompatible. In such cases, 
the incorrect brain function should be evaluated using another, 
non-invasive examination, for example magnetoencephalography 
(MEG), as well as SPECT and PET. PET scans using 18FDG, which 
during the interictal period show hypometabolism in the epileptic 
focal point, was the first imaging technique used prior to planned 
treatment with temporal lobe epilepsy [63]. Scans combining MR 
and 18FDG PET in pre-operative evaluation of an epileptic focus have 
been verified by Lee and Salamon [64]. They documented that 
a combination of MR and PET images improves identification of 
the focal point and results of surgical epilepsy treatment.
Simultaneous PET and MR imaging is also very beneficial 
in the case of complex brain activity scans, in which quick brain 
signal fluctuations should be monitored on many levels. Addition-
ally, hybrid PET/MR will enable simultaneous evaluation of var-
ious neurochemical and functional parameters which are involved 
in cognitive processes, e.g. observation of the nicotine receptor 
use and parallel BOLD fMRI — assessment of the blood oxygen 
level dependent MRI signal intensity.
Conclusions
The quantitative approach to hybrid PET/MR imaging has be-
come the area of extensive research. The physical and technical 
aspects which could potentially influence the quantitative approach 
to the PET portion of PET/MR imaging, especially attenuation cor-
rection, are still being studied and developed. At the current stage 
of technological development, PET/MR systems are based on 
two methods of imaging, namely tandem devices, equipped with 
elements combining both devices and software used to integrate 
images, and fully integrated systems.
Data gathered so far regarding the application of PET/MR 
devices in clinical setting, especially in oncology and neurology, 
is promising and it significantly exceed the potential of using those 
imaging methods separately. Additionally, the integrated PET/MR 
system is an alternative to PET/CT if a low dose of radiation 
is required, namely when examining children and when multiple 
images are required. However, further research is warranted in 
order to test the diagnostic accuracy of PET/MR. It seems that the 
predominant opinion of the involved researchers is that PET/MR and 
PET/CT will play a complementary role in different clinical situations.
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